Literature DB >> 6194252

Combined chemotherapy of cutaneous herpes simplex infection of the guinea pig.

U Burkhardt, R Wigand.   

Abstract

Cutaneous infection of guinea pigs with HSV1 was topically treated from 2 to 6 days post infection with 7 antiherpetic substances. Phosphonoformic acid and acyclovir were found to be highly effective; trifluorothymidine, thymine arabinoside, ethyldeoxyuridine, and adenine arabinoside monophosphate all had some therapeutic effect in decreasing order, whereas iododeoxyuridine was ineffective. The efficacy of treatment was evaluated from cutaneous lesion scores by the Wilcoxon rank test. The substances were combined in marginally effective concentrations. From the 21 combinations, acyclovir + phosphonoformic acid, acyclovir + thymine arabinoside, and phosphonoformic acid + thymine arabinoside suggested a synergistic interaction, which appeared significant for acyclovir + phosphonoformic acid.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6194252     DOI: 10.1002/jmv.1890120208

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

1.  Cutaneous herpes simplex virus infection of the guinea pig: lack of resistance to acyclovir and phosphonoformic acid after topical treatment.

Authors:  A Poryo; R Wigand
Journal:  Med Microbiol Immunol       Date:  1984       Impact factor: 3.402

2.  Effect of azone and propylene glycol on penetration of trifluorothymidine through skin and efficacy of different topical formulations against cutaneous herpes simplex virus infections in guinea pigs.

Authors:  S L Spruance; M McKeough; K Sugibayashi; F Robertson; P Gaede; D S Clark
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

3.  Comparison of topically applied 5-ethyl-2'-deoxyuridine and acyclovir in the treatment of cutaneous herpes simplex virus infection in guinea pigs.

Authors:  S L Spruance; D J Freeman; N V Sheth
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.